Tag: M.W:200-300

1210048-05-7, 7-Bromo-5-fluoroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 365-Fluoro-7-[3-(piperidin-l-ylmethyl)phenyllquinoxalineGlyoxal (10 drops of a 40% solution in water) was added to a solution of 5- bromo-2,3-diaminofluorobenzene (82 mg, 0.4 mmol) in ethanol (3 mL). The mixture was stirred and left to stand at r.t. for 1 h. The mixture was partitioned between water and EtOAc (20 mL each), and the organic phase was dried (MgSO4) and concentrated in vacuo. The residue was dissolved in DME (1.2 mL), and 3-(piperidin-l-ylmethyl)phenyl- boronic acid pinacol ester hydrochloride (135 mg, 0.4 mmol), 2M aqueous sodium carbonate solution (0.6 mL, 0.9 mmol) and Pd(PPh3)4 (14 mg, 0.012 mmol) were added. The mixture was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. The mixture was partitioned between water and EtOAc (2 mL each), and the organic phase was concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (23 mg, 18% over the two steps) as a pale yellow-brown gum. deltaH (CDCl3) 8.94 (d, IH), 8.89 (d, IH), 8.17 (s, IH), 7.80 (d, IH), 7.72 (s, IH), 7.64 (d, IH), 7.48 (t, IH), 7.43 (d, IH), 3.64 (s, 2H), 2.40-2.60 (m, 4H), 1.55-1.70 (m, 4H), 1.39- 1.54 (m, 2H). LCMS (ES+) 322 (M+H)+, RT 2.25 minutes., 1210048-05-7

As the paragraph descriping shows that 1210048-05-7 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

98416-72-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.98416-72-9,6-Bromo-2-chloro-3-methylquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: Method B: 4-[(4-substituted phenylimino)methyl]phenol(0.01 mol) was dissolved in acetonitrile (50 mL). Anhydrous potassiumcarbonate (2.0 g) was added to the mixture, which wasrefluxed for 1 h, then (5, 0.01 mol) was added and the mixturewas further refluxed for 8 h (monitored by TLC). After completionof the reaction, the mixture was filtered and the excess of acetonitrilewas evaporated under reduced pressure to produce the correspondingcompounds

The synthetic route of 98416-72-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R.; Eissa, Sally I.; Ammar, Yousry A.; Bioorganic and Medicinal Chemistry; vol. 23; 20; (2015); p. 6560 – 6572;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, After adding 6-bromoquinoxaline (3.8 g, 18.2 mmol), n-butyl vinyl ether (12.3 mL, 95.2 mmol), potassium carbonate (3.1 g, 22.8 mmol), 1,3-bis(diphenylphosphino)propane (504 mg, 1.3 mmol) and palladium(II) acetate (124 mg, 0.5 mmol) to N,N-dimethylformamide (47 mL) and water (6 mL), the result was stirred and refluxed for 6 hours. After terminating the reaction, the result was cooled to room temperature, 2 N hydrochloric acid was added thereto, and the result was stirred for 0.5 hours. Ethyl acetate was added thereto, the organic layer was washed with water and sodium bicarbonate, dried using anhydrous magnesium sulfate, and filtered. The filtrate was concentrated and purified using column chromatography to obtain a target compound (2.4 g). 1H NMR spectrum (300 MHz, DMSO-d6) delta 10.05(d, 1H), 9.73(t, 1H), 8.71(s, 1H), 7.97(d, 1H), 3.16(s, 3H).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Hanmi Pharmaceutical Co., Ltd.; LEE, Kyung Ik; JUNG, Young Hee; SONG, Ji Young; JUN, Seung Ah; (89 pag.)EP3480193; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, To 6-bromo-quinoxaline (1 g) in acetonitrile (25 mL) was added propargyl alcohol (0.285 mL) and triethylamine (1.334 mL) followed by copper(I) iodide (10 mg) and bis(triphenylphosphine)palladium chloride (34 mg). The reaction mixture was stirred under nitrogen and then heated at 800C for 18h. The mixture was allowed to cool and then filtered. The filtrate was evaporated and then purified by chromatography on silica eluting with ethylacetate / isohexane (1 : 1 to 1 : 0) to afford the sub-titled compound as a solid (0.7 g).1H NMR (400 MHz, DMSO) I’ 8.97 (2H, dd), 8.13 (IH, d), 8.10 (IH, d), 7.84 (IH, dd), 5.45 (IH, t), 4.39 (2H, d).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; ARGENTA DISCOVERY LIMITED; ASTRAZENECA AB; WO2009/153536; (2009); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

A solution containing 6-bromo-quinoxaline (417 mg, 2.0 mmol), 4-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert- butyl ester (600 mg, 1.94 mmol), tetrakis [triphenylphosphine] palladium (108 mg, 0.1 mmol) and sodium carbonate (2 M solution, 3 mL) in 5 ml_ of dioxane/ethanol/water (7:3:1 ) was heated at 160 C using microwave reactor for 15 minutes. After the reaction, ethylacetate was added and the mixture was filtered, washed with water. After concentration under vacuum, the product was purified using column chromatography (5% methanol in dichloromethane)

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SCHERING CORPORATION; WO2008/156739; (2008); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, To a degassed stirred solution of 6-bromo quinoxaline (2.0 g, 9.50 mmol) in toluene (20 mL), 1- ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) followed by Pd(PPh3)2CI2 (0.67 g, 0.95 mmol) were added at RT and stirred at 90 C overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT, filtered through celite and the obtained filtrate was evaporated under vacuum. To the resulting crude mixture, 6 N HCI solution (20 mL) was added and the mixture was stirred at RT for 1 h. The solution was neutralized with sat. NaHC03 and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layer was dried over Na2S04 and concentrated under vacuum. The resulting crude material was purified by flash chromatography (Biotage Isolera, eluent: 30% EtOAc in hexane) to afford the title compound. Yield: 45% (800 mg, brown solid). 1H NMR (400 MHz, DMSO-tf6): delta 9.06-9.04 (m, 2H), 8.70 (d, J = 2.4 Hz, 1 H), 8.28 (dd, J = 8.8, 2.8 Hz, 1 H), 8.16 (d, J = 8.4 Hz, 1 H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.2 min, 99.1 % (Max).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASCENEURON S.A.; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (134 pag.)WO2019/37860; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

55687-02-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

6-bromo, 2-chloroquinoxaline (0.35 g 1.4 mmol) was dissolved in DMSO (12 ml_) at room temperature and (R)-1-(3-Chloro-phenyl)-ethylamine (0.44 g, 2.8 mmol) was added. The reaction mixture was stirred at RT for 16 hours. After completion of the reaction (confirmed by TLC), water (10OmL) was added to the reaction mixture and it was extracted with ethyl acetate (50 mL x 3). The organic layer was washed with water (15 mL), brine (15 mL), and then dried over Na2SO4. The organic layer was concentrated in vacuo to afford the crude product.The crude product was adsorbed on 60-120 mesh silica gel and purified by column chromatography using neutral silica gel of 60-120 mesh size. A gradient of 0.5 % methanol in DCM was used for elution of the title compound (0.380 g, 72%).

As the paragraph descriping shows that 55687-02-0 is playing an increasingly important role.

Reference£º
Patent; SENTINEL ONCOLOGY LIMITED; BOYLE, Robert, George; WALKER, David, Winter; WO2010/136755; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

To a solution of 6-bromoquinoxaline (500 mg, 2.39 mmol, 1 eq.) in 1,4-dioxane (10 mL) was added 5-(4,4,5,5-Bis(pinacolato)diboron (729 mg, 2.87 mmol, 1.2 eq.), KOAc (469 mg, 4.78 mmol, 2 eq.), and PdCl2dppf?DCM complex (195 mg, 0.23 mmol, 0.1 eq.). The reaction mixture was deoxygenated with N2 allowed stir at 80 C. for 18 h. The reaction mixture was cooled to RT, diluted with water (50 mL) and extracted with ethyl acetate (2*50 mL). Combined organic layer was washed with brine (20 mL) and dried over sodium sulfate. Removal of solvent under reduced pressure gave crude which was purified by normal phase Combi-flash column chromatography (0-100% EtOAC-Hexane) to afford quinoxalin-6-ylboronic acid (350 mg, 85%) as brown oil.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GiraFpharma LLC; PHAM, Son Minh; CHEN, Jiyun; ANSARI, Amantullah; JADHAVAR, Pradeep S.; PATIL, Varshavekumar S.; KHAN, Farha; RAMACHANDRAN, Sreekanth A.; AGARWAL, Anil Kumar; CHAKRAVARTY, Sarvajit; (120 pag.)US2019/23666; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

2379-60-4, 2 3-Dichloro-6-nitroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A. 3-Chloro-2-hydrazino-6-nitroquinoxaline A mixture of 6.1 g (25 mmol) of 2,3-dichloro-6-nitroquinoxaline and 2.75 g (55 mmol) of hydrazine hydrate in 150 ml of ethanol was stirred at room temperature over night. The precipitate was isolated and washed with water, cold ethanol and ether to give 5.67 g (95%) of crude product., 2379-60-4

The synthetic route of 2379-60-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Novo Nordisk A/S; US5504085; (1996); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.82019-32-7,7-Bromo-1-methyl-1H-quinoxalin-2-one,as a common compound, the synthetic route is as follows.

Bis(neopentyl glycolato)diboron (1.42 mg, 6.30 mmol) and potassium acetate (823 mg, 8.40 mmol) were added to a solution of 7-bromo-1-methylquinoxalin-2(1H)-one (1.0 g, 4.2 mmol) in 1,4-dioxane (15 mL). The reaction mixture was degassed under nitrogen for 30 min before Pd(dppf)Cl2.DCM (171 mg, 0.21 mmol) was added. The reaction mixture was heated at 80 C. for 3 h. After this time the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography eluting with 30% EtOAc in iso-hexane to afford an orange solid. Trituration with diethyl ether afforded the title compound as an off-white solid (340 mg, 30%). 1H NMR (400 MHz, CDCl3): delta 8.37-8.30 (m, 1H), 7.79 (m, 3H), 3.82 (s, 4H), 3.75 (s, 3H), 1.06 (s, 6H)., 82019-32-7

The synthetic route of 82019-32-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTRAZENECA AB; LONN, Hans Roland; CONNOLLY, Stephen; SWALLOW, Steven; KARLSSON, Staffan PO; AURELL, Carl-Johan; PONTEN, John Fritiof; DOYLE, Kevin James; VAN DE POEL, Amanda Jane; JONES, Graham Peter; WATSON, David Wyn; MACRITCHIE, Jaqueline Anne; PALMER, Nicholas John; US2015/210655; (2015); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider